Pharmacy Place LLC Under DEA Scrutiny—Order Issued
Published Date: 10/30/2025
Notice
Summary
Pharmacy Place, LLC in Houston had its DEA registration suspended and is facing revocation because it filled many controlled substance prescriptions improperly and broke recordkeeping rules. This decision protects public health by stopping unsafe pharmacy practices. Pharmacy Place must fix these issues or lose its ability to handle controlled drugs, affecting their business and customers starting now.
Analyzed Economic Effects
3 provisions identified: 0 benefits, 3 costs, 0 mixed.
DEA Revokes Pharmacy Place's Registration
The Drug Enforcement Administration revoked Pharmacy Place, LLC's DEA Certificate of Registration No. FP8885785, effective December 1, 2025. This means Pharmacy Place may no longer dispense controlled substances (DEA-controlled drugs), after findings that it unlawfully released over 10,000 controlled-substance tablets over a 16-month period.
Pending Renewal and Registration Applications Denied
The Order also denies any pending application by Pharmacy Place, LLC to renew or modify Certificate No. FP8885785, and denies any other pending registration application by Pharmacy Place in Texas. That denial accompanies the revocation and is effective December 1, 2025.
Decision Emphasizes Deterrence for Registrant Community
The Agency expressly states that specific and general deterrence weigh in favor of revocation, meaning the revocation is intended to deter similar misconduct by this registrant and other DEA registrants. The decision highlights deterrence as a reason to revoke rather than impose a lesser sanction.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
2026-10090 — Exempt Chemical Preparations Under the Controlled Substances Act
The Drug Enforcement Administration (DEA) reviewed and decided on applications for special chemical mixtures that don’t fall under strict drug rules, covering requests from July 2025 to March 2026. Some mixtures got approved, others denied, and a few listings were fixed from earlier notices. If you’re involved with these chemicals, you’ve got until July 20, 2026, to share your thoughts—no fees or big costs involved, just your voice!
2026-09566 — Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
Starting May 13, 2026, the DEA officially puts CUMYL-PEGACLONE—a chemical that can be risky—into Schedule I, the strictest drug category. This means anyone making, selling, or using it now faces tough rules and penalties. This move helps the U.S. follow international drug laws and keeps communities safer without any new fees or costs.
2026-08587 — Importer of Controlled Substances Application: ANI Pharmaceuticals Inc.
ANI Pharmaceuticals wants to import certain controlled drugs like Levorphanol and Tapentadol. People who make or use these drugs can share their thoughts or ask for a hearing by June 3, 2026. This move could affect drug availability and regulation, so keep an eye on the deadline to have your say!
2026-08588 — Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.
Patheon API Inc. wants to make large amounts of special research drugs like dimethyltryptamine and psilocybin. This affects researchers and companies involved in clinical trials, with a chance to comment or ask for a hearing by July 6, 2026. No money changes are mentioned, but this move could speed up important medical studies.
Previous / Next Documents
Previous: 2025-19707 — Dawn Evert, N.P.; Decision and Order
Dawn Evert, a nurse practitioner from Colorado, had her DEA registration suspended and then revoked because she prescribed dangerous drugs without proper medical reasons or monitoring. This decision protects public safety by stopping her from legally prescribing controlled substances. The revocation is final, even though her registration expired in August 2025, so she can’t prescribe these drugs anymore.
Next: 2025-19709 — Tracy Amerson-Rivers, A.P.R.N.; Decision and Order
Tracy Amerson-Rivers, an advanced practice nurse from Texas, had her DEA registration suspended and then revoked because she prescribed controlled drugs without the required doctor’s approval and was accused of fraud. This means she can no longer legally prescribe these medications, protecting public safety. The revocation is final, even though her registration expired in June 2025, and it sends a clear message about following the rules.